尖峰集团：子公司主动撤回药品注册临床试验申请

Core Viewpoint - The company announced that its wholly-owned subsidiary, Jianfeng Pharmaceutical, has received a termination notice from the National Medical Products Administration regarding the drug registration application for "C2235 and C2235 tablets," which was voluntarily withdrawn by the company to improve related research before resubmitting the clinical trial application [1] Group 1 - Jianfeng Pharmaceutical received a termination notice for the drug registration application for "C2235 and C2235 tablets" [1] - The withdrawal of the application is a proactive measure by the company to enhance its research [1] - The withdrawal of the clinical trial application will not have a significant impact on the company's current performance [1]